Residency · Staten Island, NY
Sponsored by Zucker School of Medicine at Hofstra/Northwell
177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial.
Lancet (London, England) · 2024 · 270 citations · Xiaolin Wei
Evolution of myeloid-mediated immunotherapy resistance in prostate cancer.
Nature · 2025 · 153 citations · Xiaolin Wei
Epidural stimulation of the cervical spinal cord for post-stroke upper-limb paresis.
Nature medicine · 2023 · 137 citations · Souvik Roy
Quantitative 68Ga-PSMA-11 PET and Clinical Outcomes in Metastatic Castration-resistant Prostate Cancer Following 177Lu-PSMA-617 (VISION Trial).
Radiology · 2024 · 97 citations · Xiaolin Wei
Final overall survival and safety analyses of the phase III PSMAfore trial of [177Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancer.
Annals of oncology : official journal of the European Society for Medical Oncology · 2025 · 41 citations · Xiaolin Wei
A prospective study of long-term outcomes among hospitalized COVID-19 patients with and without neurological complications.
Journal of the neurological sciences · 2021 · 159 citations ·
The Double Antibody Drug Conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma.
Annals of oncology : official journal of the European Society for Medical Oncology · 2024 · 78 citations · Xiaolin Wei
Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial.
The Lancet. Oncology · 2023 · 95 citations · Xiaolin Wei